Church, Cameron
Fay, Christian X.
Kriukov, Emil
Liu, Hui
Cannon, Ashley
Baldwin, Lauren Ashley
Crossman, David K.
Korf, Bruce
Wallace, Margaret R.
Gross, Andrea M.
Widemann, Brigitte C.
Kesterson, Robert A.
Baranov, Petr
Wallis, Deeann http://orcid.org/0000-0002-8217-0892
Funding for this research was provided by:
Neurofibromatosis Therapy Acceleration Program
Cancer Therapy Evaluation Program
Gilbert Family Foundation
School of Medicine, University of Alabama at Birmingham
Alexion Pharmaceuticals
Article History
Received: 28 March 2024
Accepted: 9 June 2024
First Online: 21 June 2024
Declarations
:
: Human subjects and all sample collection and use were approved by the Institutional Review Board at The University of Alabama at Birmingham and conformed to NIH guidelines. Written informed consent was obtained from patients participating in clinical trial number NCT02839720.
: Not applicable.
: All financial and non-financial competing interests must be declared in this section. Bruce Korf is on medical advisory boards for Alexion, SpringWorks, Healx, Infixion, and Recursion. All other authors have no competing interests to declare.